NTRK1 and cancer: This was followed in June of 2019 by the approval of entrectinib in Japan by the Ministry of Health, Labour and Welfare, and in August of 2019 by the US FDA for the treatment of adult and paediatric patients (age 12 years and above, US FDA) with advanced or recurrent TRK fusion-positive cancers.